Arterburn Publications

  1. Hapuarachchige S, Bryant BK, Arterburn JB. Synthesis of pyridin-2-yl hydrazone rhenium(I) tricarbonyl complexes that exhibit pH-sensitive fluorescence. Chemistry of Heterocyclic Compounds 2014, 50, 254-263 DOI: 10.1007/s10593-014-1469-4. Published in Khimiya Geterotsiklicheskikh Soedinenii, No. 2, pp. 280-290, February, 2014.
  2. Vargas-Medrano J, Krishnamachari S, Villanueva E, Godfrey W, Lou H, Ramesh C, Arterburn JB, Perez R. Novel FTY720-Based Compounds Stimulate Neurotrophin Expression and Phosphatase Activity in Dopaminergic Cells.ACS Medicinal Chemistry Letters 2014, 5(7), 782-6.
  3. Nayak TK, Ramesh C, Hathaway HJ, Norenberg JP, Arterburn JB, Prossnitz ER. GPER-targeted, 99mTc-labeled, nonsteroidal ligands demonstrate selective tumor imaging and in vivo estrogen binding. Molecular Cancer Research 2014, 12, 1635-1643.
  4. Meyer MR, Fredette NC, Howard TA, Chu C, Ramesh C, Daniel C, Amann K, Arterburn JB, Barton M, Prossnitz ER. G Protein-Coupled Estrogen Receptor Protects from Atherosclerosis. Scientific Reports 2014, in press.
  5. Prossnitz ER, Arterburn JB. G protein-coupled Estrogen Receptor (GPER) and its Pharmacologic Modulators. Pharmacological Reviews 2014, in press.
  6. Brailoiu GC, Arterburn JB, Oprea TI, Chitravanshi VC, Brailoiu E. Bradycardic effects mediated by activation of G protein-coupled estrogen receptor in rat nucleus ambiguous. Experimental Physiology 2013, 98(3):679-91. doi: 10.1113/expphysiol.2012.069377. PMC3578005
  7. Brailoiu GC, Benamar K, Arterburn JB, Gao E, Rabinowitz JE, Koch WJ, Brailoiu E. Aldosterone increases cardiac vagal tone via GPER activation. J Physiol. 2013, 591, 4223-35. PMC3779113
  8. Jang EJ, Seok YM, Arterburn JB, Olatunji LA, Kim IK. GPER-1 agonist G1 induces vasorelaxation through activation of epidermal growth factor receptor-dependent signaling pathway. Journal of Pharmacy and Pharmacology 2013, 65, 1488-99. PMID 24028616.
  9. Petrie W, Dennis MK, Hu C, Dai D, Arterburn JB, Smith HO, Hathaway HJ, Prossnitz ER. G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth. Obstetrics and Gynecology International 2013, 2013; 472720, doi: 10.1155/2013/472720. PMC3863501
  10. Deliu E, Brailoiu GC, Arterburn JB, Oprea TI, Benamar K, Dun NJ, Brailoiu. Mechanisms of G Protein-Coupled Estrogen Receptor-Mediated Spinal Nociception. J. Pain 2012, 13(8) 742-754
  11. Burai R, Ramesh C, Nayak TK, Dennis MK, Bryant BK, Prossnitz ER, Arterburn JB. Synthesis and characterization of tricarbonyl-Re/Tc(I) chelate probes targeting the G protein-coupled estrogen receptor GPER/GPR30. PLoS One 2012, 7(10): e46861. DOI:10.1371/journal.pone.0046861. PMC3471960
  12. Gros R, Ding Q, Sklar LA, Prossnitz ER, Arterburn JB, Chorazyczewski J, Feldman RD. GPR30 Expression is requirted for the mineralcorticoid receptor-independent rapid vascular effects of Hypertension, 2011, 57, 442-51.
  13. Hapuarachchige S, Montaño G, Ramesh C, Rodriguez D, Henson LH, Williams CC, Kadavakkollu S, Johnson DL, Shuster CB, Arterburn JB. Design and Synthesis of a New Class of Membrane-Permeable Triazaborolopyridinium Fluorescent Probes. J Am Chem Soc. 2011, 133, 6780-6790. PMC3244355
  14. Rodriguez D, Ramesh C, Henson LH, Wilmeth L, Bryant BK, Kadavakollu S, Hirsch R, Montoya J, Howell PR, George JM, Alexander D, Johnson DL, B. Arterburn, and Shuster CB. Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity. Bioorg. Medicinal Chemistry, 2011, 5446-5453.PMC3171608
  15. Dennis MK, Field AS, Burai R, Ramesh C, Petrie WK, Bologa CG, Oprea TI, Yamaguchi Y, Hayashi S, Sklar LA, Hathaway HJ, Arterburn JB, Prossnitz ER. Identification of a GPER/GPR30 Antagonist with improved estrogen receptor counterselectivity. Steroid Biochemistry and Molecular Biology, 2011, 127, 358-66. PMC3220788.
  16. Tica AA, Dun EC, Tica OS, Gao X, Arterburn JB, Brailoiu GC, Oprea TI, Brailoiu E. G Protein-coupled estrogen receptor 1-mediated effects in the rat myometrium. Am J Physiol Cell Pysiol. 2011, 301, C1262-9. PMC3213913
  17. “Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity” Rodriguez D, Ramesh C, Henson LH, Wilmeth L, Bryant BK, Kadavakollu S, Hirsch R, Montoya J, Howell PR, George JM, Alexander D, Johnson DL, J.B. Arterburn, and Shuster CB, 2011 in press.
  18. “Identification of a GPER/GPR30 Antagonist with Improved Estrogen Receptor Counterselectivity” Dennis MK, Field AS, Burai R, Ramesh C, Petrie WK, Bologa CG, Oprea TI, Yamaguchi Y, Hayashi S, Sklar LA, Hathaway HJ, Arterburn JB, Prossnitz ER, J. Steroid Biochemistry and Molecular Biology, 2011, in press.
  19. “Design and Synthesis of a New Class of Membrane-Permeable Triazaborolopyridinium Fluorescent Probes” Hapuarachchige S, Montaño G, Ramesh C, Rodriguez D, Henson LH, Williams CC, Kadavakkollu S, Johnson DL, Shuster CB, Arterburn JB, J Am Chem Soc., 2011, 133, 6780-6790.
  20. “GPR30 Expression is requirted for the mineralcorticoid receptor-independent rapid vascular effects of aldosterone” Robert Gros, Qingming Ding, Larry A. Sklar, Eric E. Prossnitz, Jeffrey B. Arterburn, Jozef Chorazyczewski and Ross D. Feldman, Hypertension, 2011, 57, 442-51.
  21. “Influence of charge on cell permeability and tumor imaging of GPR30-targeted 111In-labeled non-steroidal imaging agents” Tapan K. Nayak, Megan K. Dennis, Chinnasamy Ramesh, Ritwik Burai, Robert W. Atcher, Larry A. Sklar, Helen J. Hathaway, Jeffrey P. Norenberg, Jeffrey B. Arterburn, Eric R. Prossnitz, ACS Chemical Biology 2010, 5, 681-690.
  22. “Highly efficient synthesis and characterization of the GPR30-Selective Agonist G-1 and related tetrahydroquinoline analogs” Ritwik Burai, Chinnasamy Ramesh, Marvin Shorty, Ramona Curpan, Cristian Bologa, Larry A. Sklar, Tudor Oprea, Eric R. Prossnitz and Jeffrey B. Arterburn, Organic and Biomolecular Chemistry, 2010 8, 2252-2259.
  23. A novel nucleoside analog, 1-β-D-ribofuranosyl-3-ethynyl-[1,2,4]triazole (ETAR), exhibits efficacy against a broad range of flaviviruses in vitro”, Michael McDowell, Sarah R. Gonzales, Sidath C. Kumarapperuma, Marjan Jeselnik, Jeffrey B. Arterburn, Kathryn A. Hanley, Antiviral Research, 2010, 87, 78-80.
  24. “The G Protein-Coupled Receptor GPR30 Inhibits Proliferation of Estrogen Receptor-Positive Breast Cancer Cells” Eric A. Ariazi, Eugen Brailoiu, Smitha Yerrum, Heather A. Shupp, Michael J. Slifker, Heather E. Cunliffe, Michael A. Black, Anne L. Donato, Jeffrey B. Arterburn, Tudor I. Oprea, Eric R. Prossnitz, Nae J. Dun, and V. Craig Jordan Cancer Research, 2010, 70, 1184-1194.
  25. “Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30” Chinnasamy Ramesh, Tapan K. Nayak, Ritwik Burai, Megan K. Dennis, Helen J. Hathaway, Larry A. Sklar, Eric R. Prossnitz, and Jeffrey B. Arterburn, Journal of Medicinal Chemistry, 2010, 53 (3), 1004–1014.
  26. “Discovery of selective probes and antagonists for G-protein-coupled receptors FPR/FPRL1 and GPR30” Jeffrey B. Arterburn, Tudor I. Oprea, Eric R. Prossnitz, Bruce S. Edwards, Larry A. Sklar. Current Topics in Medicinal Chemistry, 2009; 9, 1227-1236.
  27. “Synthesis and anti-Hantaan virus activity of N1-3-fluorophenyl-inosine” Chung DH, Strouse JJ, Sun Y, Arterburn JB, Parker WB, Jonsson CB, Antiviral Research 2009; 83(1):80-85.
  28. “In vivo effects of a GPR30 antagonist” Megan K. Dennis, Ritwik Burai, Chinnasamy Ramesh, Whitney K. Petrie, Sara N. Alcon, Tapan K. Nayak, Cristian G. Bologa, Andrei Leitao, Eugen Brailoiu, Elena Deliu, Nae J. Dun, Larry A. Sklar, Helen J. Hathaway, Jeffrey B. Arterburn, Tudor I. Oprea, Eric R. Prossnitz, Nature Chemical Biology 2009; 5(6), 421-427.
  29. “Duplex high-throughput flow cytometry screen identifies two novel formylpeptide receptor family probes” Young SM, Bologa CM, Fara D, Bryant BK, Strouse JJ, Arterburn JB, Ye RD, Oprea TI, Prossnitz ER, Sklar LA, Edwards BS, Cytometry A. 2009; 75A (3): 253-263.
  30. “Expression of estrogen receptor GPR30 in the rat spinal cord, autonomic and sensory ganglia” Siok L. Dun, G. Cristina Brailoiu, Xin Gao, Eugen Brailoiu, Jeffrey B. Arterburn, Eric R. Prossnitz, Tudor Oprea, Nae J. Dun, Journal of Neuroscience Research 2009; 87: 1610-1619.
  31. “Estrogen Signaling through the TransmembraneG protein-coupled Receptor GPR30” Eric R. Prossnitz, Jeffrey B. Arterburn, Harriet O. Smith, Tudor I. Oprea, Larry A. Sklar, and Helen J. Hathaway, Ann. Rev. Physiol. 2008; (70):165-190.
  32. “Bisphenol A directly targets tubulin to disrupt spindle organization in embryonic and somatic cells” Olivia George, Bj K. Bryant, Chinnasamy Ramesh, Cesear Corona, Jeffrey B. Arterburn and Charles B. Shuster, ACS Chemical Biology 2008; (3):167-179.
  33. “Synthesis of 1-β-D-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its In Vitro and In Vivo Efficacy Against Hantaviruses” Dong-Hoon Chung, Sidath C. Kumarapperuma, Yanjie Sun, Qianjun Li, Yong-Kyu Chu, Jeffrey B. Arterburn, William B. Parker, Jeffrey Smith, Kristen Spik, Harish Ramanathan, Connie S. Schmaljohn, and Colleen B. Jonsson, Antiviral Research 2008; (79):19-27.
  34. “Pre-clinical development of a neutral, estrogen receptor-targeted tridentate 99mTc(I) estradiol pyridine-2-yl hydrazine derivative for imaging of breast and endometrial cancers” Tapan K. Nayak, Helen H. Hathaway, Chinnasamy Ramesh, Jeffrey B. Arterburn, Donghai Dai, Larry A. Sklar, Jeffrey P. Norenberg and Eric R. Prossnitz, J. Nucl. Med. 2008 June; 49(6):978-986.
  35. “GPR30: a novel therapeutic target in estrogen-related disease” Eric R. Prossnitz, Larry A. Sklar, Tudor I. Oprea, and Jeffrey B. Arterburn, (2008) Trends in Pharmaceutical Science; 29(3):116-123.
  36. “Estrogen Signaling through the TransmembraneG protein-coupled Receptor GPR30” Eric R. Prossnitz, Jeffrey B. Arterburn, Harriet O. Smith, Tudor I. Oprea, Larry A. Sklar, and Helen J. Hathaway, (2008) Ann. Rev. Physiol. (70):165-190.
  37. “The ins and outs of GPR30: A transmembrane estrogen receptor” Eric R. Prossnitz, Tudor I. Oprea, Larry A. Sklar, Jeffrey B. Arterburn, Journal of Steroid Biochemistry & Molecular Biology 2008; 109, (3), 350-353.
  38. “Structural effects on the phosphorylation of 3-substituted 1-β-D-ribofuranosyl-1,2,4-triazoles by human adenosine kinase”, Sidath C. Kumarapperuma, Yanjie Sun, Marjan Jeselnik, Kiwon Chung, William B. Parker, Colleen B. Jonsson, Jeffrey B. Arterburn, (2007). Bioorg. Med. Chem. Lett. 17, 3203-3207.
  39. “Synthetic Estrogen Ligands Demonstrate the Functionality of Intracellular GPR30” Chetana M. Revankar, Hugh Mitchell, Ritwik Burai, Cesear Corona, Chinnasamy Ramesh, Larry A. Sklar, Jeffrey Arterburn, and Eric R. Prossnitz, ACS Chemical Biology 2007, ASAP Article; DOI: 10.1021/cb700072n.
  40. “Ribavirin Reveals a Lethal Threshold of Allowable Mutation Frequency” Dong-Hoon Chung, Yanjie Sun, William Parker, Jeffrey Arterburn, Al Bartolucci, and Colleen B. Jonsson, (2007). J.Virology 81, 11722-11729.
  41. “Virtual and Biomolecular Screening Converge on a Selective Agonist for GPR30” Cristian G. Bologa, Chetana M. Revankar, Susan M. Young, Bruce S. Edwards, Jeffrey B. Arterburn, Matthew A. Parker, Sergey E. Tkachenko, Nikolay P. Savchuck, Larry A. Sklar, Tudor I. Oprea* and Eric R. Prossnitz, Nature Chemical Biology  (2006) 2, 207-212.
  42. “Synthesis of a biotin-derived alkyne for Pd-catalyzed coupling reactions” Cesear Corona, Bj K. Bryant, Jeffrey B. Arterburn, Org. Letters 2006. 8, 1883-1886.
  43. “Steroid-binding GPCRs: New Drug Discovery Targets for Old Ligands?” Eric R. Prossnitz, Jeffrey B. Arterburn, Bruce S. Edwards, Larry A. Sklar, Tudor I. Oprea (2006) Expert Opinion in Drug Discovery 1(2)137-150.
  44. “Linkage Effects on Binding Affinity and Activation of GPR30 and Estrogen Receptors ER/ with Tridentate Pyridin-2-yl Hydrazine Tricarbonyl-Re/99mTc(I) Chelates” Chinasamy Ramesh, Bj, K. Bryant, Tapan Nayak, Chetana M. Revankar, Tamara Anderson, Jeffrey P. Norenberg, Kathryn E. Carlson, John A. Katzenellenbogen, Larry A. Sklar, Eric R. Prossnitz, Jeffrey B. Arterburn, (2006) J. Am. Chem. Soc. 128, 14476-14477.
  45. “Characterization of a radiolabeled small molecule targeting LFA-1 expression in lymphoma and leukemia” Rahul B. Poria, Jeffrey P. Norenberg, Tamara L. Anderson, Carston R. Wagner, Jeffrey B. Arterburn, Richard S. Larson (2006) Cancer Biotherapy and Radiopharmaceuticals, 21, No 5, 418-426.
  46. “GPR30: A G protein-coupled receptor for estrogen” Eric R. Prossnitz, Jeffrey B. Arterburn, Larry A. Sklar (2007) Molecular and Cellular Endocrinology 265-266, 138-142.
  47. “A Transmembrane Intracellular Estrogen Receptor Mediates Rapid Cell Signaling” Chetana M. Revankar, Daniel F. Cimino, Larry A. Sklar, Jeffrey B. Arterburn, Eric R. Prossnitz Science (2005) 307, 1625-1630.
  48. “Potential Importance of Error Catastrophe to the Development of Antiviral Strategies for Hantaviruses” Colleen B. Jonsson, Brook G. Milligan, and Jeffrey B. Arterburn, Virus Research 2005, 307, 195-205.
  49. “Copper catalyzed arylation with boronic acids for the synthesis of N1-aryl purine nucleosides”, J. Jacob Strouse, Marjan Jeselnik, Fredrick Tapaha, Colleen B. Jonsson, Jeffrey B. Arterburn, Tetrahedron Letters (2005) 46, 5699-5702.
  50. “Applications of boronic acids in selective C-C and C-N arylation of purines”, J. Jacob Strouse, Marjan Jeselnik, Jeffrey B. Arterburn, Acta Chim. Slov. (2005) 52, 187-199.